Balance sheets don’t tell the whole story. This is especially true for biotech companies where pre-revenue businesses can still be worth billions of dollars with the innovative medicines they are creating.
On a macro level, biotech companies outperformed the S&P 500 and both pharmaceutical and medtech sectors in terms of total returns to shareholders over the past 20 years, to a total of over USD $1.7 trillion in total shareholder value.
The looming uptick in cancer rates has spurred a renewed urgency amongst scientists and researchers to develop novel oncology therapeutics. There is commercial impetus too with sales from therapeutics in the global oncology market are forecast to hit $250 billion by 2024.
The world’s leading healthcare market, the United States, offers an especially lucrative opportunity for biotech companies, should they gain the holy grail- FDA approval.
There are many companies working towards solutions for oncology’s biggest questions and area of highest unmet need, and not just the pharmaceutical giants. The ASX is home to many smaller companies with equally promising clinical pipelines, offering investors the chance to get in on the ground floor of a potentially high value medicine.
When looking for that hidden gem, investors often have to wade through paragraphs of scientific jargon to evaluate their chosen stock. It can be difficult to assess clinical trial results, the level of market demand and the science behind a company’s assets. In an effort to take the guesswork out, we’ve picked a handful of these oncology focussed companies from the ranks and have assessed their scientific platforms, progress to date and financials.
To download our report in full for free, simply register in the form provided.
Companies covered:
- Pharmaxis (ASX: PXS)
- Imugene (ASX: IMU)
- Noxopharm (ASX: NOX)
- Rhythm Biosciences (ASX: RHY)
- Kazia Therapeutics (ASX: KZA)
- Chimeric Therapeutics (ASX: CHM